Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20747674 | 0.93 | CA2 (0.39) | LMNACA2CA1 | |
| SCHEMBL16795949 | 0.87 | FAAH (0.41) | FAAHLMNACA2CNR1CNR2 | |
| SCHEMBL16973566 | 0.87 | FAAH (0.41) | FAAHLMNACA2CNR1CNR2 | |
| SCHEMBL20747713 | 0.86 | METAP1 (0.36) | — | |
| SCHEMBL20747595 | 0.86 | CA2 (0.41) | FAAHLMNACA2GRIK1GRIK2 | |
| SCHEMBL20747668 | 0.79 | MAPT (0.35) | — | |
| SCHEMBL20747756 | 0.77 | CA2 (0.37) | LMNACA2CA1 | |
| SCHEMBL305594 | 0.75 | HCAR2 (0.42) | FAAHLMNACNR1CNR2SMPD1 | |
| SCHEMBL20747615 | 0.74 | ACE2 (0.45) | FAAHLMNACA2GRIK1GRIK2 | |
| SCHEMBL1301214 | 0.72 | ACE2 (0.50) | FAAHLMNACNR1CNR2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | FAAH 4432/4885LMNA 2972/4885CA2 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.